Xspray Pharma AB (publ) (STO:XSPRAY)

Market Cap	477.96M -71.5%
Revenue (ttm)	2.47M
Net Income	-159.44M
EPS	-3.82
Shares Out	47.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,123
Open	10.06
Previous Close	10.06
Day's Range	9.90 - 10.12
52-Week Range	9.69 - 64.10
Beta	-0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XSPRAY

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error